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Case scenario
A 4 year old girl, has been brought to the clinic by her parents 
due to three episodes of coughing and wheezing, with the first 
episode occurring approximately 6 months previously. The child 
has a history of eczema and her mother suffered from asthma. 
The father is a smoker. This is a case of asthma in childhood. 
What is the cause of asthma and how is such a case managed 
in general practice?
 
Introduction
Asthma is the commonest chronic lung disease in children 
characterized by chronic inflammation of the airways leading 
to obstruction of airflow.1,2 This may be completely or partially 
reversed with or without specific therapy.   Asthma exacerbations 
are episodic but airway inflammation is chronically present.3 
Estimates of prevalence of asthma range from 7% in France 
and Germany to 11% in the USA and 15 to 18% in the United 
Kingdom. Approximately 20% of these patients have severe 
asthma, of which 20% is inadequately controlled.4 Peak age of 
onset is 5 years, where it is more common in boys than girls, at a 
ratio of 3:2.5  During adolescence, the prevalence is equal among 
males and females. Globally, morbidity and mortality associated 
with asthma have increased over the last 2 decades.2
Predisposing and triggering factors
The development of asthma in childhood is due to an interaction 
between environmental and genetic factors. There is no 
single gene for asthma.6,7  Asthma is associated with a genetic 
predisposition to atopy, with an atopic component present in 
40% of patients, in the form of a personal or familial history of 
eczema, hay fever and urticaria.5 Approximately 79% to 90% of 
children with asthma have allergy.8 
Common environmental triggers for asthma include 
exposure to allergens such as those from house dust mites, 
animals with fur, cockraoches, pollen, molds and tobacco smoke.3 
However the “hygiene hypothesis” claims that living in a clean 
environment predisposes the immune system towards allergic 
reactivity. In fact a large number of studies have consistently 
shown that growing up on a farm in various rural areas in Europe 
confers protection from the development of hay fever, atopic 
sensitization and asthma from childhood into young adulthood.9 
The early exposure to other children, domestic animals and less 
frequent use of antibiotics also has a protective effect.8 Exposure 
to environmental tobacco smoke  worsens asthma control. 
Reduced smoking in the home and for young adults smoking 
restriction on the work place may lower the prevalence of 
asthma, improve asthma control, and reduce the use of medical 
services.10 A bidirectional relationship might also be present 
between asthma and smoking in adolescents. Non-smoking 
adolescents with current diagnosed asthma and with more 
severe asthma have an increased risk to become regular smokers. 
Among girls and adolescents with a smoking mother, having 
asthma symptoms can be protective for experimental smoking. 
With regards to the effect of smoking on asthma, adolescent 
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smoking predicts a higher incidence of asthma symptoms. In 
addition, smoking leads to an increased symptom severity score, 
and this effect seems to be stronger in girls. 11   There is also 
evidence for an association between asthma and air pollutants, 
including ozone, NO2 and particulate matter. Air pollution 
research is evolving rapidly and in the near future, clinicians 
and public health agencies may provide recommendations for 
asthmatics that go beyond paying attention to the air-pollution 
forecast.12 Viral infections are important triggers of asthma. 
Infants hospitalized with bronchiolitis are at significantly 
increased risk for both recurrent wheezing and childhood 
asthma. It is not known whether viral bronchiolitis directly 
contributes to asthma causation or simply identifies infants at 
risk for subsequent wheezing. Alternatively the properties of 
the infecting virus may be important. A genetic susceptibility 
to asthma after viral bronchiolitis might be present.13 Bacterial 
infections may also be responsible. In fact neonates colonized in 
the hypopharyngeal region with S. pneumoniae, H. influenzae 
or M. catarrhalis, or with a combination of these organisms, are 
at increased risk for recurrent wheeze and asthma early in life.14 
Asthma and excessive body weight frequently coexist. Excessive 
body weight is associated with an additional decrease in quality 
of life in children with asthma.15   Other triggers include exercise, 
cold air, strong emotional expressions, (e.g. laughing and crying) 
chemical irritants, drugs such as aspirin and beta blockers and 
aggravating conditions not appropriately treated (e.g. rhinitis, 
sinusitis, gastroesophageal reflux).3,8
Clinical features
Asthma is characterized by recurring episodes of wheezing, 
breathlessness, chest tightness and coughing. Between attacks 
the child may be asymptomatic with no abnormal physical 
signs.5 A history of persistent cough (cough-variant asthma), 
night coughs, exercise induced cough, post-tussive emesis from 
copious amounts of mucus and cough following cold air exposure 
are all suggestive of asthma. Abdominal pain is common owing 
to the use of accessory muscles.1    The child may also complain of 
Table 1: Consider asthma if any of the following signs or 
symptoms are present3:
•	 Frequent episodes of wheezing – more than once a 
month
•	 Activity-induced cough or wheeze
•	 Cough particularly at night during periods without 
viral infections
•	 Absence of seasonal variation in wheeze
•	 Symptoms persist after three years of age
•	 Symptoms occur or worsen in the presence of 
triggering factors
•	 The child’s colds repeatedly “go to the chest” or take 
more than 10 days to clear up. 
•	 Symptoms improve when asthma medication is given
Table 2: Differential diagnosis of wheezing 1
Respiratory causes
(Common)
•	Infection
•	Foreign body
•	Cystic fibrosis
•	Laryngotracheomalacia
(Uncommon)
•	Bronchopulmonary dysplasia
•	a1-antitrypsin deficiency
•	Allergic bronchopulmonary aspergillosis
•	Ciliary dyskinesia syndrome
•	Hypersensitivity pneumonitis
•	Bronchiectasis
•	Pulmonary hemosiderosis
•	Visceral larva migrans – hypereosinophilic disorders
Cardiovascular causes
•	Congenital heart disease
•	Vascular rings/slings
Gastrointestinal
•	Gastroesophageal reflux
•	H-type tracheo-esophageal fistula
•	Foreign body
Miscellaneous
•	Immunodeficiency disorder
•	Vasculitis, collagen vascular disease
•	Psychogenic cough
Consider alternate diagnosis if 8
•	Failure to thrive
•	Cyanosis at feeding
•	Vomiting at feeding
•	Failure to respond to appropriate treatment
•	Clubbing 
fatigue and becomes easily irritated. Infants may have difficulty 
feeding or may grunt during sucking. Older children may avoid 
certain activities such as sports and sleep-overs.8 Most children 
who develop wheezing after 5 years of age have asthma.3 The 
nature of wheezing changes with the severity of the asthma. In 
the mildest form, wheezing is only end-expiratory. As severity 
increases, the wheeze lasts throughout expiration, and may even 
be present during inspiration. In most severe cases, air flow may 
be so limited that wheezing may be absent.2  
Any child with asthma can experience a life-threatening 
episode.8 During acute episodes, the physical examination 
may reveal a hyper-inflated chest that is hyper-resonant 
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Table 3: The Peak Flow Zone System8
>80% *GREEN ZONE: Good control
• No asthma symptoms
• Take medications as usual
50-80%* YELLOW ZONE: Caution
• Use a short-acting inhaled b2-agonist
• Check about changing medications or increasing dose
<50%* RED ZONE – Medical alert
• Use a short-acting inhaled b2-agonist
• Call doctor or emergency department
to percussion. Tachypnea, tachycardia, cough, inspiratory 
and expiratory wheezing, and a prolonged expiratory phase 
are common clinical signs. As the attack progresses there is 
cyanosis, use of accessory muscles of respiration, decreased 
breath sounds (tight silent chest) and diminished wheezing, 
agitation and inability to speak, tripod sitting position, and 
pulsus paradoxus.1
 If the child is in imminent respiratory arrest, in addition 
to the aforementioned symptoms, there is drowsiness and 
confusion. However, adolescents may not have these symptoms 
until they are in frank respiratory failure.2
Diagnosis
Asthma can be diagnosed on the basis of the patient’s 
symptoms and medical history (Table 1). This disease is 
frequently under-diagnosed and many patients do not receive 
adequate therapy. On the other hand, not all wheeze and cough 
are caused by asthma and caution is needed to avoid prescribing 
asthma therapy unnecessarily (Table 2).3
Lung function measurement helps diagnosis and also 
assessment of asthma severity. Spirometry is the preferred 
method, but this may not be feasible in young children, 
particularly under the age of 4 years. Moreover some children 
cannot conduct the manoeuvre adequately until after age 7. 
For these children, the diagnosis of asthma has to be based 
largely on clinical judgement and an assessment of symptoms 
and physical findings and usually on the response to a trail of 
inhaled bronchodilator and/or corticosteroid therapy.3 Newer 
techniques, such as a measurement of airway resistance using 
impulse oscillormetry system are being evaluated for this 
population of patients.2 In children who can perform spirometry 
an increase in FEV1 of more than or equal to 12% or 200ml 
after administration of a bronchiodilator indicates reversible 
airflow limitation consistent with asthma. However most asthma 
patients will not exhibit reversibility at each assessment, and 
repeated testing is advised.
Peak expiratory flow  (PEF) measurements can also be 
utilised in monitoring of asthma. PEF measurements are ideally 
compared to the patient’s own previous best measurements 
using his/her own peak flow meter. A diary of symptoms and 
PEF readings should be kept. An improvement of 60L/min (or 
≥ 30% of the prebronchodilator PEF) after the inhalation of a 
bronchodilator, or diurnal variation of PEF of more than 20% 
(with twice daily readings, more than 10%) suggests uncontrolled 
asthma.3 Patients and parents can be advised on how to alter 
their treatment according to the PEF values (Table 3).
Chest radiographs in both posteroanterior and lateral 
views should be obtained in all new wheezing patients to 
identify anatomic abnormalities, atelactasis, foreign bodies 
or neoplasms.1 If the child is a known asthmatic and there 
is not suspicion of infection, radiology is not required for 
every admission.5 If a full blood count is taken it may show an 
eosinophilia. Allergy testing is recommended for children with 
persistent asthma who are exposed to perennial indoor allergens 
and is helpful for diagnosing relevant allergic factors that may 
contribute to asthma severity.8
Treatment
Asthma can be primarily treated in the community with 
most patients achieving good control of their disease. 5 A holistic 
approach is required.  
Patient, family and doctor partnership
and education
The children and their families need to be actively involved 
in managing asthma. Education should begin at the time of the 
diagnosis and continue at every step of clinical care. Knowledge 
about avoiding risk factors, how to take the medication correctly 
and understanding the difference between controller and 
reliever medications is crucial for optimal control, together 
with information on how to monitor the asthma control status, 
recognize signs of worsening asthma and take the appropriate 
action.3 A written personal asthma action plan that is appropriate 
and practical should be prepared with the collaboration of the 
doctor, child, and family members3 since a relationship between 
parental beliefs about asthma medications and medication 
adherence exists.17  As children grow older they need education 
about what is happening especially adolescents who would 
benefit from receiving all information themselves.8 Using known 
personalities who themselves have asthma and using teen 
support groups can be very affective.  Parents should support the 
teenager’s efforts toward self-management, but still be involved 
in their children’s care.  
Children with asthma require regular monitoring. 
Information about symptom patterns over the past 2 weeks 
(particularly night and early morning symptoms) and school 
absenteeism and limitation of daily activities due to asthma 
should be sought. For infants it is important to ask about 
difficulty with feeding, changes in respiratory rate, retractions, 
irritability and weight loss.
The older child spends a substantial amount of hours at 
school. The school should be given an action plan including 
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early warning signs of an asthma episode, what medications 
the student uses and how they should be taken. The parents 
should be encouraged to meet with the teacher, school nurse 
and perhaps the principal at the beginning of the school year to 
make them aware of the child’s needs regarding asthma.8
Identifying and reducing 
exposure to risk factors
Allergen avoidance can produce changes in disease 
activity and symptoms, before any medical intervention is 
implemented.18,19 Smoking must be avoided around the child, 
therefore smoking cessation plans for parents and care givers 
need to be implemented as part of asthma management. 
Dust mites can be limited by encasing the child’s mattress in 
an allergen-impermeable cover and cover the pillow in and 
allergen impermeable case, which need to be washed weekly at a 
temperature of 130oF (55oC). Desirable actions include removing 
carpets from the bedroom and from rooms that are laid on 
cement. Stuffed toys should be minimized from the child’s 
bedroom and washed weekly in hot water. Pets should ideally 
be removed from home but if this is not acceptable they should 
be kept out of the child’s bedroom and washed weekly.8 Physical 
activity can cause asthma symptoms but patients should not 
avoid exercise. Symptoms can be prevented by taking a rapid-
acting inhaled b2-agonist before strenuous exercise (leukotreine 
receptor antagonists or cromolyn are alternatives).27 
Pharmacological management
– stepwise approach
Pharmacologic management includes the use of control 
agents such as inhaled corticosteroids, inhaled, long-
acting bronchodilators, theophylline, leukotriene receptor 
antagonists, and recently introduced strategies such as the use 
of anti-IgE antibodies. Relief medications include short-acting 
bronchodilators, systemic corticosteroids and ipratropium.2 A 
stepwise approach to pharmacologic treatment to achieve and 
maintain control of asthma should be used (Tables 4 and 5). 
A child should start treatment at the step appropriate to the 
initial severity.
Monitoring and maintaining control
Treatment should be reviewed every 1 to 3 months after 
the initial visit and every three months thereafter. After an 
exacerbation follow up should be offered within two weeks to 
one month.3 Before stepping up treatment, the appropriateness 
of the inhaler and the technique being used should be assessed. 
If control is achieved step wise reduction to the lowest possible 
corticosteroid dose may be possible. The dose must be reduced 
slowly, with a reduction being considered every 3 months and 
be decreased by up to 50% each time.20 Any exacerbation should 
prompt review of maintenance treatment. By definition any 
exacerbation in any week indicates uncontrolled asthma.
Pharmacological management 
– drug information
b2-adrenergic agonist inhalation therapy is best reserved 
for acute symptomatic episodes of wheezing rather than being 
used for routine chronic therapy during asymptomatic periods. 
Commonly reported potential side effects include a fine tremor, 
headache and palpitations. 20
Table 4: Stepwise approach to the management of 
asthma in children aged 5 to 18 years 20
Step 
Occasional use of inhaled short-acting b2-agonists (ISABA)
Step 2
(if above are used more than once a week, or exacerbations 
requiring systemic steroids or nebulised bronchodilators) 
ISABA as required
+
Regular standard dose inhaled corticosteroids
Step 
ISABA as required
+
Regular standard dose inhaled corticosteroids
+
Inhaled long-acting b2-agonist 
If no response:
Discontinue long-acting b2-agonist
Increase dose of inhaled corticosteroids to upper end of 
standard dose
If still no response:
Add one of leukotriene receptor antagonist, modified 
release theophylline, or modified release oral b2-agonists
Step 4
Inhaled short-acting b2-agonist as required
+
Regular high dose inhaled corticosteroids
+
Inhaled long acting b2-agonist
+
6 week therapeutic trial of one or more of leukotrien 
receptor antagonist, modified release theophylline or 
modified release oral b2-agonist
Step 5
If persistent poor control refer to respiratory specialist
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Table 5: Stepwise approach in the management of 
asthma in children younger than 5 years of age:
Step 
Short acting b2-agonist as required – Preferably inhaled, 
since more effective and less side effects than oral
Step 2 
(if above are used for more than twice a week or night 
time symptoms or exacerbations)
Inhaled short acting b2-agonist
+
Regular standard dose of inhaled corticosteroids (ICS), 
of leukotriene receptor antagonist or theophylline if ICS 
cannot be used.
Step 
Under 2 years: refer to respiratory specialist
2 to 5 years: 
Inhaled short acting b2-agonists
+
Regular standard dose inhaled corticosteroids
+
Leukotriene receptor antagonist
Step 4
If persistent poor control refer to respiratory specialist. 
Inhaled corticosteroids (ICS) can cause side effects. This 
depends on the formulation, dosing and device used, and 
the subject’s age, severity of asthma and inhaler technique.22 
Administration of inhaled steroids at or above 400µg per day of 
beclomethasone dipropionate or equivalent and administration 
of long term oral steroids e.g. longer than 3 months or three to 
four courses per year may be associated with systemic side effects 
such as growth suppression. However there is little evidence for 
reduction in long-term growth at normal doses.21  Nevertheless 
it is important to monitor child’s height on regular basis and 
screen for development of cataracts if high doses are being used.5 
Growth deceleration of asthmatic children on maintenance 
ICS is compensated for after the first 12 months of treatment. 
This effect does not differ between budesonide or fluticasone 
propionate, despite some variation in the pattern of linear 
growth.23 At above-licensed doses, biochemical adrencortical 
suppression can occur with some unusual but documented cases 
of clinical Addisonian crisis. Limited evidence in paediatric age 
groups would suggest that ciclesonide may have some advantage 
although it is not as yet licensed in all countries.21   Hypertrichosis 
may be a useful clinical pointer to exogenous steroid excess.24 
Hoarseness and candidiasis of the mouth or throat have been 
reported. This can be reduced by using a spacer device and by 
rinsing the mouth with water after inhalation.20 
There a strong scientific rationale for single inhaler therapy 
in asthma. The use of the single inhaler combining salmeterol/
fluticasone propionate provided a statistically significant 
improvement in lung function and in symptoms but provided 
no significantly increased protection against exacerbations 
when compared to increased doses of inhaled corticosteroids 
in patients with asthma.25 In patients with mild asthma, the 
symptom-driven use of inhaled beclomethasone (250µg) 
and salbutamol (100µg) in a single inhaler is as effective as 
regular use of inhaled beclomethasone (250µg twice daily) 
and is associated with a lower 6 month cumulative dose of 
the inhaled corticosterods.26 Using a budesonide/formoterol 
combination inhaler as regular maintenance treatment twice 
daily but also as a rescue therapy for breakthrough symptoms 
can provide more effective control of asthma, particularly in 
reducing exacerbations, than using a short-acting b2-agonist or 
formoterol as rescue therapy.27  There is insufficient evidence 
at present to recommend the use of combination products 
rather than increased moderate doses of ICSs as a first-line 
treatment for patients uncontrolled on their current doses of 
ICSs. Combination therapy should be prescribed to patients 
with moderate to severe asthma after daily long-term treatment 
with inhaled corticosteroids has been tried without obtaining 
adequate control and it is not indicated to be used as first line 
treatment in asthma.28
Steroids are not always prescribed as indicated by guidelines. 
Pediatricians and family physicians reported different barriers 
to prescribing daily inhaled corticosteroids for children with 
persistent asthma. Although both groups indicated that parent 
hesitancy and non adherence were common barriers, the most 
common barrier for family physicians was a perceived cost of 
the asthma medications for families. Pediatricians were more 
likely to indicate that lack of time (21% vs 10%) was a barrier 
to prescribing inhaled corticosteroids.29
A leukotriene receptor antagonist can be used as a preventer 
if inhaled steroids are contra indicated.5 Recently the use of 
motelukast has been approved for children aged 2 years and older. 
In moderately persistent asthma, low or medium-dose inhaled 
corticosteroids combined with a long acting bronchodilator or 
leukotriene antagonist can be used, especially for the control of 
nocturnal or exercise-induced symptoms.2  When montelukast 
was prescribed as an add on to the usual therapy, there was a 
53%reduction in days with worse asthma symptoms compared 
with placebo and a 78% reduction in unscheduled physician 
visits for asthma. The benefit of montelukast was seen both in 
those using and not using regular inhaled corticosteroids. Boys 
aged 2 to 5 years showed greater benefit from montelukast than 
did older boys, whereas among girls the treatment effect was 
most evident in 10 to 14 year olds, with non significant effects 
in younger girls.30 Montelukast has a rapid onset of action and 
may be effective if used intermittently. If treatment is initiated 
at the onset of each upper respiratory tract infection or asthma 
symptoms and continued for a minimum of 7 days or until 
symptoms had resolved for 48 hours, there is a modest reduction 
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in acute health care resource utilization, symptoms, time off 
from school and parental time off from work in children with 
intermittent asthma.31
Theophylline and long acting b2-agonists are bronchodilators 
used for the management of persistent asthma symptoms, 
especially nocturnal asthma. They represent different classes of 
drug with differing side-effect profile. Theophylline preparations 
are becoming less attractive because of a narrow therapeutic 
index and complex pharmacokinetics. Long acting b2-agonists 
particularly salmeterol are more effective than theophylline in 
improving morning and evening PEF but are not significantly 
different in their effect on FEV1. There is evidence of decreased 
daytime and nighttime short-acting b2-agonist requirement 
with salmeterol. Fewer adverse events occurred in participants 
using long-acting b2-agonists (salmeterol and formoterol) as 
compared to theophylline.32
Patients with moderate-to-severe asthma who react to 
perennial allergens despite inhaled corticosteroids may benefit 
from the anti-Ig E monoclonal antibody omalizumab treatment. 
When used as an add-on therapy to inhaled corticosteroids, 
omalizumab reduced mean asthma exacerbation as confirmed 
by improvements in other measurements of asthma control, 
including symptom scores. 2
Selection of best inhaler device
Inhaled medications are preferred since they are more 
effective than syrups and have fewer systemic side effects.5 
Devices available to deliver inhaled medication include 
pressurized-metered-dose inhalers (pMDIs) breath-actuated 
metered-dose inhalers, dry powder inhalers (DPIs) and 
nebulisers. For children younger than 5 years a pressurized 
metered dose inhaler should be used with a spacer with a face 
mask if necessary. If this is not effective and depending on 
the child’s condition, nebulised therapy may be considered. 
In children older than 3 years of age a dry powder inhaler 
may also be considered. In a child aged between 5 to 15 years 
corticosteroids should be given via a pMDI and a spacer. 20
Spacer or valved holding-chamber, devices make inhalers 
easier to use especially in infants and children with poor 
inhalation technique and reduce systemic absorption and side-
effects of inhaled glucocorticosteriods.3  The spacer device must 
be compatible with the prescribed MDI. As soon as a child is 
able to use a mouth piece this is the preferred delivery system. 
Advice regarding the care of spacers should be given to parents 
and children. The device should be cleansed once a month by 
washing in a mild detergent and then allowed to dry in air. The 
mouthpiece should be wiped clean of detergent before use. More 
frequent cleaning should be avoided since any electrostatic 
charge may effect drug delivery. Spacers should be replaced 
every 6 to 11 months.20
Acute asthma exacerbations
Exacerbations of asthma are episodes of a progressive 
increase in shortness of breath, cough, wheezing or chest 
tightness, or a combination of these symptoms.3
The respiratory rate, heart rate, oxygen saturation (SpO2 
over 92%) and peak expiratory flow (every 1 to 4 hours) should 
be monitored. Recognizing acute severe symptoms is of crucial 
importance  (Table 6). 
Acute mild to moderate exacerbation 
in a child under 2 years of age
A short acting b2-agonist using a pressurized meter 
dosed inhaler with a spacer device and a close fitting mask is 
recommended. One puff must be given every 15 to 30 seconds 
up to a maximum of 10 puffs. This dose can be repeated after 
20 to 30 minutes. If response is poor or if relapse occurs within 
3 to 4 hours the child should be transferred immediately to 
hospital.20
Acute mild to moderated exacerbations 
of asthma in a child between 
2 and 8 years of age
A short acting b2-agonist via a pMDI with a spacer device (if 
younger than 5 years with a close fitting mask) should be given. 
One puff every 15 to 30 seconds can be given up to a maximum 
of 10 puffs. Treatment can be repeated after 20 to 30 minutes. 
In all cases oral prednisolone at a dose of 1 to 2 mg per kg (max 
40mg) should be given once daily for 3 to 5 days. If response is 
poor or relapse occurs within 3 to 4 hours the child should be 
transferred immediately to hospital.
Indications for hospital admission
Indications for hospital admission include:
• failure to respond to or early deterioration after inhaled 
bronchodilators 
Table 6: Recognition of acute severe asthma in children5
The child is:
• too breathless too talk 
• too breathless too feed 
• respiration is more than 50 breaths/min 
• pulse is more than 140 beats/min 
• PEF is less 50% best or predicted
• Using accessory muscles to breath 
In life threatening acute severe asthma:
• PEF less than 33% of best or predicted 
• cyanosis, poor respiratory effort or silent chest 
• fatigue or exhaustion 
• agitation or reduction in level of consciousness
Note : children may not appear distressed despite 
suffering a severe attack - this makes assessment of the 
very young very difficult.
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• inability of the child to take or the parents to give 
appropriate treatment 
• request for admission from the general practitioner 
• severe breathlessness and increasing tiredness 
• peak expiratory flow less than 50% of the expected value 
10 minutes after treatment5
Prognosis 
Asthma is known to have a direct impact on the quality 
of life of children and their families.33   Poor asthma control is 
associated with a substantial degree of impairment.34  Each year, 
children with asthma miss more than 14 million school days, 
which may negatively affect grades, academic achievement, 
self-esteem, and future life successes.  Parents also miss from 
their time off work. Disturbed sleep from night-time asthma 
symptoms can also decrease productivity at work for parents and 
at school for children.8  In adolescents, the presence of at least 
four wheezing attacks during the previous year was associated 
with relevant deficits in quality of life.35  Asthma has also been 
related to a higher risk of psychological problems.36 However 
children with well-controlled asthma can have a normal life 
style. It is therefore crucial for the well being of patients and 
their families that asthma is well controlled (Table 7). 
The majority of children with asthma will have fewer 
symptoms as they grow older. Over half of those patients with 
infrequent episodes of asthma will stop being symptomatic in 
adult life.5 Risk factors for persisting asthma symptoms into 
adulthood include, early age of onset and requiring frequent 
periods of hospital treatment, ongoing eczema, chronic lung 
abnormalities and the combination of smoking.5
Patients should be reminded that asthma is not a cause for 
shame. Olympic athletes, famous leaders, other celebrities and 
ordinary people live successful lives with asthma.3
Conclusion
The girl in the above clinical scenario had widespread 
wheezing at the time of the examination. The diagnosis of 
asthma was based on the history and the clinical finding since 
the child could not perform peak expiratory flow measurements 
in view of her young age. The parents were given verbal and 
printed information about asthma. The patient was prescribed 
salbutamol 2 puffs four times a day for four days followed by 2 
puffs three times a day for 3 more days, via a pMDI and a spacer 
with a face mask.  Since this was the third episode of wheezing 
she was also prescribed inhaled beclamethasone as 2 puffs in 
the morning and evening for 7 days followed by 2 puffs in the 
evening till the next visit. The parents were advised to limit 
triggering factors in the child’s environment. Review had to 
occur within one month and there were also plans to address 
the need for the father smoking cessation in the following 
appointments. 
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